Le Lézard
Classified in: Health
Subject: SVY

Amino Acid Metabolism Disorders Treatment Market: Global Industry Analysis (2012 - 2016) & Opportunity Assessment (2017 - 2026)


LONDON, August 16, 2018 /PRNewswire/ -- Amino acids are those organic compounds that contain carboxyl (-COOH) and amine (-NH2) functional groups together with a lateral chain (R group) specific to each amino acid. The core rudiments of an amino acid are carbon (C), oxygen (O), hydrogen (H), and nitrogen (N), though other rudiments are discovered in the side chains of some amino acids. Around 500 naturally taking place amino acids are recognized, however only 20 are visible in the genetic code, and can be segmented in countless ways. One metabolic disorder is also associated with amino acid. Amino acids are "building blocks" that consolidate to frame proteins. In the event that one have one of these issues, the body may experience difficulty separating certain amino acids. Or on the other hand there might be an issue getting the amino acids into the cells. These issues cause a development of destructive substances in the body. That can prompt genuine, now and again dangerous, medical issues. These clutters are generally acquired. A child who is conceived with one might not have any indications immediately. Since the disorders can be so genuine, early analysis and treatment are basic. Infants get screened for a considerable lot of them, utilizing blood tests. Medications may incorporate uncommon eating regimens, drugs, and supplements. A few infants may likewise require extra medicines if there are complexities.

Download the full report: https://www.reportbuyer.com/product/5392481

Future Market Insights (FMI) has published a new research report on the global amino acids metabolism disorders treatment market that covers several crucial points pertaining to the growth track of the global market. Dynamics such as drivers, important trends, information about market players, restraints, strategies, product portfolio, and policies have been highlighted in the report. The report also provides the peruser with data pertaining to the future, present, and past of the market. Data related to the regions and other segments have also been offered in the study. .

According to FMI, the global amino acid metabolism disorders treatment market is projected to rise at a stable CAGR from 2017 to 2026. The market is projected to touch a valuation of over US$1,030 Mn by the end of the forecast period.

North America to Lead Trailed by Europe

North America is anticipated to retain a foremost position in the market by the end of the forecast period touching a valuation of over US$359 Mn. It is expected to be closely followed by Europe. Players operating in this market can seek potential opportunities from the U.S., Germany, Spain, and France owing to numerous clinical trials taking place pertaining to this treatment and several mergers and acquisitions occurring among core players operating in these regions. Players can also find lucrative opportunities from Asia Pacific excluding Japan and as well with the rise in nutritional management activities in these regions. Countries in APAC such as China and India are also anticipated to emerge as potential adopters of amino acid metabolism disorders treatment in the long run.

Hospital Pharmacies to be Most Preferred Sales Channel

On the basis of sales channel, the global market for amino acid metabolism disorder treatment has been classified into hospital pharmacies, retail pharmacies, and online sales. Hospital pharmacies is expected to take the lead among all these by the end of 2026. Based on product type, carglumic acid is expected to lead the market until the end of the forecast period reaching a valuation of over US$185 Mn. However, sapropterin dihydrocholoride is expected to witness the maximum growth rate over the course of the forecast period.

Competitive Landscape
The companies operating in the market are GlaxoSmithKline PLC, Pfizer, Inc., AMINO GmbH, Merck KGaA, Recordati S.p.A., Koninklijke DSM N.V., Sanofi, Shine Star (Hubei) Biological Engineering Co., Civentichem, LLC, Ltd., and Kyowa Hakko Kirin Co., Ltd.

Download the full report: https://www.reportbuyer.com/product/5392481

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

SOURCE ReportBuyer


These press releases may also interest you

at 20:25
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...

at 20:12
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...

at 19:29
Suffolk DBT is proud to announce the completion of their initial expansion to accommodate the growing need for DBT therapy...

at 18:24
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference. On April 26, 2024, the hearing will commence 11:15 a.m. Members of the public may observe the hearing by videoconference, by...

at 17:55
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....

at 17:43
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...



News published on and distributed by: